Association of heat-shock proteins in various neurodegenerative disorders: Is it a master key to open the therapeutic door?

Molecular and Cellular Biochemistry

Volumn 386, Issue 1-2, 2014, Pages 45-61

  Paul, Subhankar ^a   Mahanta, Sailendra ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Alzheimer's disease; Heat shock proteins; Hsp90 inhibitors; Misfolding and aggregation; Neurodegeneration; Parkinson disease; Polyglutamine disease; Prion disease

Indexed keywords

ALVESPIMYCIN; CELASTROL; CHAPERONIN 60; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HUMAN; NONHUMAN; PARKINSON DISEASE; POLYGLUTAMINE DISEASE; PRION DISEASE; PROTEIN FUNCTION;

HEAT-SHOCK PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING;

EID: 84891547570     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1844-y     Document Type: Article

References (145)

1. Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding diseases. Nature 426(6968):905-909
2. Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65(2):184-189
3. Muchowski PJ (2002) Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35(1):9-12
4. Forman MS, Lee VM, Trojanowski JQ (2003) 'Unfolding' pathways in neurodegenerative disease. Trends Neurosci 26(8):407-410
5. Hartl FU (1996) Molecular chaperones in cellular protein folding. Nature 381(6583):571-579. doi: 10.1038/381571a0
6. Welch WJ (2004) Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol 15(1):31-38
7. Barral JM, Broadley SA, Schaffar G, Hartl FU (2004) Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 15(1):17-29
8. Becker J, Craig EA (1994) Heat-shock proteins as molecular chaperones. Eur J Biochem 219(1-2):11-23
9. Morimoto RI, Kline MP, Bimston DN, Cotto JJ (1997) The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 32:17-29
10. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29(1):15-32
11. Slavotinek AM, Biesecker LG (2001) Unfolding the role of chaperones and chaperonins in human disease. Trends Genet 17(9):528-535
12. Macario AJL, De Macario EC, Mark PM (2001) Molecular chaperones and age-related degenerative disorders. In: Bittar E (ed) Advances in cell aging and gerontology, vol 7. Elsevier, pp 131-162. doi: 10.1016/S1566-3124(01)07018-3
13. Bukau B, Horwich AL, Cycles H (1998) The Hsp70 and Hsp60 review chaperone machines. Cell 92:351-366
14. Thirumalai D, Lorimer GH (2001) Chaperonin-mediated protein folding. Annu Rev Biophys Biomol Struct 30:245-269
15. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79(2):129-168
16. Ohtsuka K, Suzuki T (2000) Roles of molecular chaperones in the nervous system. Brain Res Bull 53(2):141-146
17. Pratt WB, Silverstein AM, Galigniana MD (1999) A model for the cytoplasmic trafficking of signalling proteins involving the Hsp90-binding immunophilins and p50cdc37. Cell Signal 11(12):839-851
18. Richter K, Buchner J (2001) Hsp90: chaperoning signal transduction. J Cell Physiol 188(3):281-290
19. Young JC, Moarefi I, Hartl FU (2001) Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154(2):267-273
20. Porankiewicz J, Wang J, Clarke AK (1999) New insights into the ATP-dependent Clp protease: Escherichia coli and beyond. Mol Microbiol 32(3):449-458
21. Arrigo AP (1998) Small stress proteins: chaperones that act as regulators of intracellular redox state and programmed cell death. Biol Chem 379(1):19-26
22. Head MW, Goldman JE (2000) Small heat shock proteins, the cytoskeleton, and inclusion body formation. Neuropathol Appl Neurobiol 26(4):304-312
23. Hightower LE (1991) Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 66(2):191-197
24. Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6(1):11-22
25. Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY, Patterson C (1999) Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 19(6):4535-4545
26. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J, Patterson C (2001) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 276(46):42938-42944
27. Luders J, Demand J, Hohfeld J (2000) The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol Chem 275(7):4613-4617
28. Cuervo AM, Dice JF (1998) Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med (Berl) 76(1):6-12
29. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761-772
30. Paul S (2008) Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. BioEssays 30(11-12):1172-1184
31. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11(3):213-228
32. Chaudhuri TK, Paul S (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 273(7):1331-1349. doi: 10.1111/j.1742-4658.2006.05181.x
33. Goedert M (2004) Tau protein and neurodegeneration. Semin Cell Dev Biol 15(1):45-49
34. Forloni G, Terreni L, Bertani I, Fogliarino S, Invernizzi R, Assini A, Ribizzi G, Negro A, Calabrese E, Volonte MA, Mariani C, Franceschi M, Tabaton M, Bertoli A (2002) Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging 23(5):957-976
35. Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43(1):1-7
36. Mouradian MM (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58(2):179-185
37. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 160(5):1655-1667
38. El-Agnaf OM, Irvine GB (2000) Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J Struct Biol 130(2-3):300-309
39. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E (2000) α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157(2):401-410
40. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20(16):6048-6054
41. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275(24):18344-18349
42. da Costa CA, Ancolio K, Checler F (2000) Wild-type but not Parkinson's disease-related ala-53->Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 275(31):24065-24069
43. Forloni G, Bertani I, Calella AM, Thaler F, Invernizzi R (2000) Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 47(5):632-640
44. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM (2000) Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97(2):279-284
45. Prusiner SB (2001) Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med 344(20):1516-1526
46. Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, Prusiner SB (1994) Structural clues to prion replication. Science 264(5158):530-531
47. Goldfarb LG, Brown P, Haltia M, Cathala F, McCombie WR, Kovanen J, Cervenakova L, Goldin L, Nieto A, Godec MS, et al. (1992) Creutzfeldt-Jakob disease cosegregates with the codon 178Asn PRNP mutation in families of European origin. Ann Neurol 31(3):274-281
48. Baskakov IV, Legname G, Prusiner SB, Cohen FE (2001) Folding of prion protein to its native alpha-helical conformation is under kinetic control. J Biol Chem 276(23):19687-19690
49. Zanata SM, Lopes MH, Mercadante AF, Hajj GN, Chiarini LB, Nomizo R, Freitas AR, Cabral AL, Lee KS, Juliano MA, de Oliveira E, Jachieri SG, Burlingame A, Huang L, Linden R, Brentani RR, Martins VR (2002) Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J 21(13):3307-3316
50. Chiarini LB, Freitas AR, Zanata SM, Brentani RR, Martins VR, Linden R (2002) Cellular prion protein transduces neuroprotective signals. EMBO J 21(13):3317-3326
51. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10:S10-S17
52. Hurtado-Lorenzo A, Anand VS (2008) Heat shock protein 90 modulates LRRK2 stability: potential implications for Parkinson's disease treatment. J Neurosci 28(27):6757-6759
53. Lian HY, Zhang H, Zhang ZR, Loovers HM, Jones GW, Rowling PJ, Itzhaki LS, Zhou JM, Perrett S (2007) Hsp40 interacts directly with the native state of the yeast prion protein Ure2 and inhibits formation of amyloid-like fibrils. J Biol Chem 282(16):11931-11940
54. Liu J, Zhang JP, Shi M, Quinn T, Bradner J, Beyer R, Chen S, Zhang J (2009) Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci 29(5):1480-1485
55. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B (1999) α-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19(14):5782-5791
56. Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet 10(12):1307-1315
57. Cisse S, Perry G, Lacoste-Royal G, Cabana T, Gauvreau D (1993) Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. Acta Neuropathol 85(3):233-240
58. Hamos JE, Oblas B, Pulaski-Salo D, Welch WJ, Bole DG, Drachman DA (1991) Expression of heat shock proteins in Alzheimer's disease. Neurology 41(3):345-350
59. Perez N, Sugar J, Charya S, Johnson G, Merril C, Bierer L, Perl D, Haroutunian V, Wallace W (1991) Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Brain Res Mol Brain Res 11(3-4):249-254
60. Renkawek K, Bosman GJ, Gaestel M (1993) Increased expression of heat-shock protein 27 kDa in Alzheimer disease: a preliminary study. NeuroReport 5(1):14-16
61. Shinohara H, Inaguma Y, Goto S, Inagaki T, Kato K (1993) Alpha B crystallin and HSP28 are enhanced in the cerebral cortex of patients with Alzheimer's disease. J Neurol Sci 119(2):203-208
62. Wyttenbach A (2004) Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis. J Mol Neurosci 23(1-2):69-96
63. Shimura H, Miura-Shimura Y, Kosik KS (2004) Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 279(17):17957-17962
64. Dedmon MM, Christodoulou J, Wilson MR, Dobson CM (2005) Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem 280(15):14733-14740
65. Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, Sakahira H, Siegers K, Hayer-Hartl M, Hartl FU (2004) Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 15(1):95-105
66. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H (2003) Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci USA 100(2):721-726
67. Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, Rubinsztein DC (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc Natl Acad Sci USA 97(17):9701-9705
68. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19(2):148-154
69. Hughes RE, Olson JM (2001) Therapeutic opportunities in polyglutamine disease. Nat Med 7(4):419-423
70. Krobitsch S, Lindquist S (2000) Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci USA 97(4):1589-1594
71. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295(5556):865-868
72. Chafekar SM, Duennwald ML (2012) Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS One 7(5):e37929
73. Lotz GP, Legleiter J, Aron R, Mitchell EJ, Huang SY, Ng C, Glabe C, Thompson LM, Muchowski PJ (2010) Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J Biol Chem 285(49):38183-38193
74. Hartl FU, Hayer-Hartl M (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295(5561):1852-1858
75. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23(4):425-428
76. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Zoghbi HY (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10(14):1511-1518
77. Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, Sobue G (2000) Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem 275(12):8772-8778
78. Bailey CK, Andriola IF, Kampinga HH, Merry DE (2002) Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet 11(5):515-523
79. Gong WJ, Golic KG (2006) Loss of Hsp70 in Drosophila is pleiotropic, with effects on thermotolerance, recovery from heat shock and neurodegeneration. Genetics 172(1):275-286
80. Sobue G (2003) Development of therapeutics for spinal and bulbar muscular atrophy (SBMA). Rinsho Shinkeigaku 43(11):909-911
81. Novoselova TV, Margulis BA, Novoselov SS, Sapozhnikov AM, van der Spuy J, Cheetham ME, Guzhova IV (2005) Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation. J Neurochem 94(3):597-606
82. Howarth JL, Glover CP, Uney JB (2009) HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J Neurochem 108(4):945-951
83. Auluck PK, Bonini NM (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 8(11):1185-1186
84. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT (2002) TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 83(4):846-854
85. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ (2004) Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 279(24):25497-25502
86. Yang Y, Turner RS, Gaut JR (1998) The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Abeta40 and Abeta42 secretion. J Biol Chem 273(40):25552-25555
87. Magrane J, Smith RC, Walsh K, Querfurth HW (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 24(7):1700-1706
88. Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, Komiyama T, Li X, Morishima Y, Merry DE, Pratt WB, Osawa Y, Collins CA, Gestwicki JE, Lieberman AP (2013) Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 9(2):112-118
89. Tantucci M, Mariucci G, Taha E, Spaccatini C, Tozzi A, Luchetti E, Calabresi P, Ambrosini MV (2009) Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment. Neuroscience 163(3):735-740
90. Voss K, Combs B, Patterson KR, Binder LI, Gamblin TC (2012) Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry 51(4):888-898
91. Patterson KR, Ward SM, Combs B, Voss K, Kanaan NM, Morfini G, Brady ST, Gamblin TC, Binder LI (2011) Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry 50(47):10300-10310
92. Hoshino T, Murao N, Namba T, Takehara M, Adachi H, Katsuno M, Sobue G, Matsushima T, Suzuki T, Mizushima T (2011) Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice. J Neurosci 31(14):5225-5234
93. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, McLean PJ (2011) Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 25(1):326-336
94. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci USA 97(14):7841-7846
95. Douglas PM, Treusch S, Ren HY, Halfmann R, Duennwald ML, Lindquist S, Cyr DM (2008) Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci USA 105(20):7206-7211
96. Sharma D, Stanley RF, Masison DC (2009) Curing of yeast [URE3] prion by the Hsp40 cochaperone Ydj1p is mediated by Hsp70. Genetics 181(1):129-137
97. Vacher C, Garcia-Oroz L, Rubinsztein DC (2005) Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 14(22):3425-3433
98. Cashikar AG, Duennwald M, Lindquist SL (2005) A chaperone pathway in protein disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104. J Biol Chem 280(25):23869-23875
99. Perrin V, Regulier E, Abbas-Terki T, Hassig R, Brouillet E, Aebischer P, Luthi-Carter R, Deglon N (2007) Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther 15(5):903-911
100. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P (2008) Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118(9):3087-3097
101. Paul S (2007) Polyglutamine-mediated neurodegeneration: use of chaperones as prevention strategy. Biochemistry (Mosc) 72(4):359-366
102. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubinsztein DC (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11(9):1137-1151
103. Liao PC, Lin HY, Yuh CH, Yu LK, Wang HD (2008) The effect of neuronal expression of heat shock proteins 26 and 27 on lifespan, neurodegeneration, and apoptosis in Drosophila. Biochem Biophys Res Commun 376(4):637-641
104. Kazemi-Esfarjani P, Benzer S (2000) Genetic suppression of polyglutamine toxicity in Drosophila. Science 287(5459):1837-1840
105. Chernoff YO, Lindquist SL, Ono B, Inge-Vechtomov SG, Liebman SW (1995) Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. Science 268(5212):880-884
106. DebBurman SK, Raymond GJ, Caughey B, Lindquist S (1997) Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci USA 94(25):13938-13943
107. Wegrzyn RD, Bapat K, Newnam GP, Zink AD, Chernoff YO (2001) Mechanism of prion loss after Hsp104 inactivation in yeast. Mol Cell Biol 21(14):4656-4669
108. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G (2006) Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med (Berl) 84(8):635-646
109. Luo W, Rodina A, Chiosis G (2008) Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? BMC Neurosci 9(Suppl 2):S7
110. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G (2007) Roles of heat shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 104:9511-9516
111. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS, Hutton M, Burrows F, Petrucelli L (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117:648-658
112. Stepanova L, Leng X, Parker SB, Harper JW (1996) Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 10(12):1491-1502
113. Dou F, Chang X, Ma D (2007) Hsp90 maintains the stability and function of the tau phosphorylating kinase GSK3ÎÂ. Int J Mol Sci 8(1):51-60
114. Klettner A (2004) The induction of heat shock proteins as a potential strategy to treat neurodegenerative disorders. Drug News Perspect 17(5):299-306
115. Brown IR (2007) Heat shock proteins and protection of the nervous system. Ann NY Acad Sci 1113(1):147-158
116. Kondo N, Katsuno M, Adachi H, Minamiyama M, Doi H, Matsumoto S, Miyazaki Y, Iida M, Tohnai G, Nakatsuji H (2013) Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nat Commun 4:1405
117. Kitson RR, Chang CH, Xiong R, Williams HE, Davis AL, Lewis W, Dehn DL, Siegel D, Roe SM, Prodromou C, Ross D, Moody CJ (2013) Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem 5(4):307-314
118. Auluck PK, Meulener MC, Bonini NM (2005) Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 280(4):2873-2878
119. Shen H-Y, He J-C, Wang Y, Huang Q-Y, Chen J-F (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280(48):39962-39969
120. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11:1088-1095
121. Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G (2006) Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG). Ann NY Acad Sci 1086:21-34
122. Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, Doi H, Tanaka K, Hamazaki J, Murata S, Tanaka F (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 18(5):898-910
123. Batulan Z, Taylor DM, Aarons RJ, Minotti S, Doroudchi MM, Nalbantoglu J, Durham HD (2006) Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol Dis 24(2):213-225
124. Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 283(38):26188-26197
125. Whitesell L, Cook P (1996) Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 10(6):705-712
126. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7(1):162-170
127. Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: molecular targets of thunder god vine. Biochem Biophys Res Commun 394(3):439-442
128. Zhang Y-Q, Sarge KD (2007) Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J Mol Med 85(12):1421-1428
129. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflamm 7:17
130. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94(4):471-480
131. Xiao X, Zuo X, Davis AA, McMillan DR, Curry BB, Richardson JA, Benjamin IJ (1999) HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J 18(21):5943-5952
132. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L (2001) Destabilization of steroid receptors by heat shock protein 90-binding drugs A ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7(7):2076-2084
133. McLean PJ, Klucken J, Shin Y, Hyman BT (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321(3):665-669
134. Nagai Y, Fujikake N, Popiel HA, Wada K (2010) Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol 11(2):188-197
135. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, McLean PJ (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther 332(3):849-857
136. Herbst M, Wanker EE (2007) Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. Neurodegener Dis 4(2-3):254-260
137. Tanaka F, Katsuno M, Banno H, Suzuki K, Adachi H, Sobue G (2012) Current status of treatment of spinal and bulbar muscular atrophy. Neural Plast 2012:8
138. Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF (2005) Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis 2(5):246-254
139. Shaaban KA, Wang X, Elshahawi SI, Ponomareva LV, Sunkara M, Copley GC, Hower JC, Morris AJ, Kharel MK, Jon S, Thorson JS, Herbimycins D-F (2013) Ansamycin analogues from Streptomyces sp. RM-7-15. J Nat Prod. doi: 10.1021/np400308w
140. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, Cai H (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28(13):3384-3391
141. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111(2):209-218
142. Turturici G, Sconzo G, Geraci F (2011) Hsp70 and its molecular role in nervous system diseases. Biochem Res Int 2011:618127
143. Mahanta S, Pilla S, Paul S (2013) Design of novel geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy. Med Hypotheses 81(3):463-469
144. Gupta UK, Mahanta S, Paul S (2013) In silico design of small peptide-based Hsp90 inhibitor: a novel anticancer agent. Med Hypotheses. doi: 10.1016/j.mehy.2013.08.006
145. Nemirovsky A, Fisher Y, Baron R, Cohen IR, Monsonego A (2011) Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. Vaccine 29(23):4043-4050